title: Emergency reversal of clopidogrel in the setting of spontaneous intracerebral hemorrhage.
abstract: OBJECTIVE
  To compare outcomes in the setting of spontaneous intracerebral hemorrhage (ICH) in patients taking aspirin (acetylsalicylic acid [ASA]) versus patients taking clopidogrel before hospitalization.
  
  
  METHODS
  Patients admitted to the neurosurgical service with a spontaneous ICH while taking an antiplatelet agent were prospectively identified and retrospectively reviewed. Two groups of 28 consecutive patients taking ASA or clopidogrel on admission were ultimately evaluated.
  
  
  RESULTS
  Patients in the clopidogrel group had a mean age of 72.6 years, and patients in the ASA group had a mean age of 65.8 years (P=0.04). Patients taking clopidogrel before hospitalization were significantly more likely than patients taking ASA to experience an increase in hematoma volume (P=0.05). Patients in the ASA group trended toward being discharged to home more frequently than other destinations (P=0.07). The in-hospital mortality rates in this series were 14.3% for the ASA group and 28.6% for the clopidogrel group. However, this association did not reach statistical significance (P=0.19).
  
  
  CONCLUSIONS
  In this study, patients taking clopidogrel showed more hematoma expansion, higher in-hospital mortality rates, and a decreased likelihood of a home discharge compared with patients taking ASA alone.
authors.affiliation: Department of Neurosurgery, Thomas Jefferson University, Jefferson Hospital for Neurosciences, Philadelphia, Pennsylvania, USA.
authors.forename: Peter G
authors.initials: PG
authors.lastname: Campbell
authors.forename: Sanjay
authors.initials: S
authors.lastname: Yadla
authors.forename: Anish N
authors.initials: AN
authors.lastname: Sen
authors.forename: Jack
authors.initials: J
authors.lastname: Jallo
authors.forename: Pascal
authors.initials: P
authors.lastname: Jabbour
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D002543:Cerebral Hemorrhage / Q000209:etiology / Q000628:therapy*; D000077144:Clopidogrel; D003627:Data Interpretation, Statistical; D004359:Drug Therapy, Combination; D004632:Emergency Medical Services; D005260:Female; D023261:Glasgow Outcome Scale; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D017713:Platelet Transfusion; D011446:Prospective Studies; D012189:Retrospective Studies; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017287:Ventriculoperitoneal Shunt; D014696:Ventriculostomy; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin